Business UpdateAug 11, 2026, 08:26 AM
PDS Biotech Prioritizes PDS0301, Halts PDS0101 Phase 3 Trial
AI Summary
PDS Biotechnology Corporation announced a strategic refocus, prioritizing the development of PDS0301, its tumor-targeted immunocytokine, as its lead program. This decision follows a comprehensive review of its portfolio and capital allocation. The company will discontinue internal investment in the PDS0101 Phase 3 VERSATILE-003 trial and seek strategic partnerships for its continued development. PDS Biotech believes PDS0301 offers a more attractive path to long-term shareholder value, citing encouraging clinical data in metastatic colorectal cancer and a broad application potential across multiple solid tumors.
Key Highlights
- PDS Biotech will cease internal investment in the PDS0101 Phase 3 VERSATILE-003 trial, discontinuing the trial.
- The company intends to pursue strategic partnerships or externally funded opportunities for PDS0101 development.
- PDS Biotech is prioritizing the advancement of PDS0301, its tumor-targeted immunocytokine, as its lead program.
- PDS0301 demonstrated a 71% objective response rate (ORR) at 6 months in metastatic MSS/pMMR colorectal cancer with liver metastases.
- PDS0301 showed an 80% 24-month survival rate in patients with metastatic MSS/pMMR colorectal cancer and liver metastases.
- More than 380 patients have been treated with PDS0301, showing an encouraging safety and tolerability profile.
- A randomized Phase 2b trial for PDS0301 has been designed, incorporating feedback from the FDA.
- The company expects to advance PDS0301 through Phase 2b and identify PDS0101 partners within 18 to 24 months.
Price Impact
More from PDSB